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The insertion of non-tunneled temporary hemodialysis
catheters (NTHCs) is a core procedure of nephrology practice.
While urgent dialysis may be life-saving, mechanical and
infectious complications related to the insertion of NTHCs
can be fatal. In recent years, various techniques that reduce
mechanical and infectious complications related to NTHCs
have been described. Evidence now suggests that ultrasound
guidance should be used for internal jugular and femoral
vein NTHC insertions. The implementation of evidence-based
infection-control ‘bundles’ for central venous catheter
insertions has significantly reduced the incidence of
bloodstream infections in the intensive care unit setting with
important implications for how nephrologists should insert
NTHCs. In addition, the Cathedia Study has provided the first
high-level evidence about the optimal site of NTHC insertion,
as it relates to the risk of infection and catheter dysfunction.
Incorporating these evidence-based techniques into a
simulation-based program for training nephrologists in NTHC
insertion has been shown to be an effective way to improve
the procedural skills of nephrology trainees. Nonetheless,
there are some data suggesting nephrologists have been
slow to adopt evidence-based practices surrounding NTHC
insertion. This mini review focuses on techniques that reduce
the complications of NTHCs and are relevant to the practice
and training of nephrologists.
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Non-tunneled temporary hemodialysis catheter (NTHC)
insertion is a required procedural skill for most nephrologists
and nephrology trainees. For all central venous catheters
(CVCs), including NTHCs, significant morbidity, mortality
and expense can be attributed to their insertion and use.1,2
Figure 1 details the more frequent and serious complications
of NTHC insertion, according to insertion site. In the past
decade, various techniques implemented at the time of
NTHC insertion have reduced the risk of mechanical and
infectious complications. However, these advances have
largely been reported in the critical care, infection control
and general internal medicine literature.
There is some evidence that the nephrology community
has not fully adopted techniques shown to reduce complica-
tions related to NTHC insertion.3 Previous work evaluating
trainees’ skills inserting NTHCs incorporated an assessment
of techniques shown to reduce complications4 and found that
procedural competency at the end of nephrology training was
poor. This is concerning because, while insertion of a NTHC
may be essential for provision of life-saving renal replacement
therapy, mechanical and infectious complications of catheter
placement can themselves be fatal and are avoidable. This
mini review of practices surrounding the use of NTHCs
focuses on recent advances that are relevant to the practice
and training of nephrologists.
USE OF ULTRASOUND GUIDANCE TO PREVENT MECHANICAL
COMPLICATIONS
Acute mechanical complications related to hemodialysis
catheter insertion, such as vascular injury or hematoma, are
common, occurring in up to 5% of catheter insertions.2 Other
mechanical complications such as pneumothorax, pneumo-
pericardium, air and guidewire embolism, and arrhythmia are
less frequent but can be fatal.2
It has been well established that the use of real-time
ultrasound guidance reduces the mechanical complications
associated with CVC insertion at the internal jugular (IJ) and
femoral sites. The benefits of ultrasound are likely largely due
to anatomic variations in IJ (Figure 2) and femoral (Figure 3)
vein locations relative to the artery.5,6 Although most data are
from studies of non-dialysis catheters, a recent systematic
review by Rabindranath et al.7 specifically focused on the use
of real-time ultrasound guidance for insertion of dialysis
catheters. Seven randomized controlled trials (RCTs) involv-
ing 767 patients and 830 IJ catheter insertions (including
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both tunneled and non-tunneled catheters inserted at the
femoral or IJ site) were included. The authors concluded that
the use of real-time ultrasound at the time of catheter
insertion resulted in a significant reduction in arterial
punctures and hematomas, improved the rate of successful
insertion on the first attempt and reduced the time taken
for successful venous puncture compared with the anatomic
landmark-guided technique with no ultrasound.7 This
accords with current recommendations regarding the use
of ultrasound for NTHC insertion by renal organizations
internationally.8,9 However, it is unclear the extent to which
these guidelines have been adopted. Ultrasound is used less
commonly for NTHC insertions at the femoral site3 which
might be expected given that there is no risk of pneumo-
thorax. Nonetheless, serious and even fatal complications
related to femoral hemodialysis catheter insertion have
been reported with the incidence of severe hemorrhage
(usually retroperitoneal) estimated at 0.5%.10 One study by
Prabhu et al.11 randomized 110 patients to real-time
ultrasound-guided anatomic landmark-guided insertion of
a femoral NTHC. The use of real-time ultrasound resulted in
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Figure 2 | Anatomic variation of the internal jugular vein relative
to the common carotid artery. Right-sided, axial section (viewed
from above). *54% of those with internal jugular veins anterolateral
to the common carotid artery overlap the artery by X75% of its
diameter. Variations not shown: lateral (0–84%) and far lateral (0–4%),
both with no overlap; up to 18% of internal jugular veins are not
visible or are thrombosed. Adapted from: Maecken T et al. Crit Care
Med 2007; 35(S5):S178.
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Figure 3 | Anatomic variation of the common femoral vein
relative to the common femoral artery. Right-sided, axial section
(viewed from above). *Over 25% overlap between the common
femoral vein and common femoral artery occurs in 8% of patients.
65% of patients have some degree of overlap. Adapted from: Baum
PA et al. Radiology 1989; 173:775-777.
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Figure 1 | Frequent and serious complications of temporary (non-
tunneled) hemodialysis catheter insertion.
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significantly better ‘first attempt’ and overall success rates
compared with the use of anatomic landmarks alone: 85.5%
vs. 54.5% (Po0.001) and 98.2% vs. 80% (P¼ 0.002), respec-
tively. In addition, the complication rate was 18.2% for the
landmark-based technique vs. 5.5% with ultrasound
guidance (P¼ 0.039). Subgroup analyses conducted accord-
ing to operator experience of more or less than 6 years did
not show any significant differences from what was observed
overall. The current level of evidence suggests that all
operators use real-time ultrasound guidance for insertion
of NTHCs at the femoral site.
EVIDENCE-BASED TECHNIQUES TO REDUCE INFECTIOUS
COMPLICATIONS
Infection-control techniques at the time of catheter insertion
Central line-associated bloodstream infections (CLABSIs)
and exit-site infections cause significant morbidity and
mortality.1 Fortunately, the overall incidence of CLABSIs in
the United States has markedly declined in recent years likely
as a result of infection-control interventions targeted to the
intensive care unit (ICU) setting.1 With respect to NTHCs in
particular, a systematic review reported that the rate of
CLABSIs for NTHCs is higher than for other types of CVCs
(4.8 vs. 2.7 per 1000 catheter days).12
In the ICU setting, multiple interventions at the time of
CVC insertion have reduced the rate of associated infec-
tions13 and include:
 adequate hand hygiene.
 maximal barrier precautions at the time of CVC insertion
(sterile gown, mask, gloves and cap) plus full head-to-toe
sterile covering of the patient using a specialized sterile
drape as opposed to a ‘standard-sized’ sterile field.
 2% chlorhexidine skin antisepsis applied using a ‘back-and-
forth’ scrubbing motion for times indicated by the manu-
facturer on dry areas (IJ site) and moist areas (femoral site).
 avoidance of the femoral site (to be discussed in more
detail below).
 systematic, daily review of the need for a catheter and
removal if no longer required.
An infection-control ‘bundle’ consists of interventions
such as these, applied together, in conjunction with staff
education, facilitation of access to the required equipment in
the form of a standardized kit and a program of nurse-led
monitoring and real-time feedback that uses a detailed checklist
to ensure compliance. Infection-control ‘bundles’ have been
shown to dramatically reduce the rate of CLABSIs14 and
subsequently maintain this reduced rate15 in the ICU setting.
While ‘bundled-interventions’ have primarily been studied in
ICUs, it is likely that this approach could be similarly effective
in the various settings that nephrologists and trainees may
insert hemodialysis catheters. This is particularly relevant
given that the reduction in CLABSIs observed in recent years
in ICUs has not been observed in other settings1 and may
reflect an opportunity for more widespread application of
these types of interventions. As such, the various aspects of
an infection-control ‘bundle’, as described, should be integrated
into the practice and training of nephrologists.
Catheter-locking solutions
The properties of different catheter-locking solutions may
influence both thrombus and biofilm formation and asso-
ciated complications of catheter malfunction and infection.
Multiple smaller-scale RCTs have shown that the use of
various antibacterial catheter locks (ACLs) for tunneled
hemodialysis catheters (and some studies including NTHCs
in addition to tunneled hemodialysis (HD) catheters) can
reduce the likelihood of infectious outcomes compared with
conventional locking solutions such as heparin alone.16 An
RCT by Maki et al.17 included 407 hemodialysis outpatients
with tunneled HD catheters and compared heparin locks
with ones containing a mixture of sodium citrate, methylene
blue, methylparaben and propylparaben (C–MB–P). The
authors demonstrated that C–MB–P locks were associated
with significantly fewer CLABSIs and were significantly less
likely to be discontinued due to poor flows.17 While this
study presents an exciting avenue for further research, it also
highlights one of the difficulties in assessing the evidence
with respect to ACLs for NTHCs: studies involving the use of
ACLs for tunneled HD catheters18,19 may not be directly
applicable to NTHCs given the different settings and clinical
circumstances in which they are typically used. One study to
focus exclusively on the use of ACLs for NTHCs was an RCT
by Kim et al.20, which included 120 new hemodialysis patients
using NTHCs while awaiting placement or maturation of
a fistula or graft. This study compared ACLs containing
gentamicin (5mg/ml), cefazolin (10mg/ml) and heparin
(1000 IU/ml) with locks containing heparin alone.20 The ACL
group had significantly fewer CLABSIs (0.44 per 1000
catheter days vs. 3.12 per 1000 catheter days, P¼ 0.031)
and no adverse events were reported.20 Although this study
did not detect any methicillin-resistant Staphyloccocus aureus
resulting from the ACLs, it was underpowered to do so.
Overall, in addition to the lack of large scale, RCT-based
evidence favoring the use of any particular ACL, there are
additional concerns that have limited their broad usage: higher
costs, practical issues related to the compounding of ACL
solutions at individual dialysis centers and, most importantly,
the possibility of promoting antibiotic resistance.16
Given the possibility of antibiotic resistance, it is an
appealing concept to utilize antimicrobial locking solutions
containing different antibiotics than those routinely used to
treat CLABSIs. A recent RCT that utilized such an approach
compared EDTA (30mg/ml)þminocycline (3mg/ml) to
heparin (5000U/ml) as the catheter lock solution in 187
catheters (144 were NTHCs).21 This study concluded that
there were no significant differences in the rate of catheter
removal for dysfunction. However, there was a significant
improvement in catheter-related bacteremia-free survival
(hazard ratio 0.32; 95% CI 0.14–0.71) and 90 day catheter-
related bacteremia-free survival (91.3% vs. 69.3%) with
EDTAþminocycline.21
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Another consideration is whether catheter locks should
contain trisodium citrate (hereafter referred to as citrate) or
heparin as the primary anticoagulant to maintain catheter
patency. A recent systematic review and meta-analysis
compared the use of citrate (with or without antimicrobials)
to heparin locks in hemodialysis catheters. This review
included 13 studies, two of which considered only NTHCs
and two that included both NTHCs and tunneled HD
catheters.22 The authors concluded that antimicrobial-
containing citrate solutions with a low to moderate concen-
tration of citrate (i.e., p4%) reduced the incidence of
CLABSIs compared with heparin-containing locks. There was
no significant difference in exit-site infections or catheter
patency.22 Locks using higher concentrations of citrate
(X30%) have been associated with additional safety con-
cerns such as hypocalcemia and arrhythmia related to
accidental systemic administration22 and were subjected to
a manufacturer’s recall in the United States for this reason.18
While variable outcome measures used across the included
studies prevented a subgroup analysis on the basis of catheter
type (NTHCs or tunneled HD catheters, specifically), the
overall conclusions accord generally with what was observed
for studies that involved NTHCs.
A 2011 study of exclusively NTHCs (n¼ 177) compared
three types of locks: 4% citrateþ 1.35% taurolidine, 5000U/ml
heparinþ gentamicin and 5000U/ml heparin alone.23 In this
study, citrateþ taurolidine significantly reduced CLABSI rates
more than heparin alone (RR: 0.37; 95% CI, 0.16–0.84).23
Overall, the evidence supports a recommendation that
citrate (p4%) locks be favored over heparin locks for
NTHCs. Currently, 4% citrate is used in most HD units in
Canada in the form of prefilled 5ml syringes (Citralok,
MED-XL, Montreal, QC, Canada)24 for patients with
tunneled HD catheters. The extent to which it is used for
NTHCs is unknown particularly given that NTHCs are often
used in ICUs or other critical care areas. It should be noted
that, in the United States, none of the most commonly
used catheter-locking solutions, including heparin at the
1000U/ml concentration, are approved by the Food and
Drug Administration for use in HD catheters.25 This also
includes 4% citrate which is only available in 250- or 500-ml
bags and requires further preparation before being used as a
catheter lock.24
While citrate catheter locks should be favored over
heparin ones, the efficacy and safety of specific ACLs that
contain antibiotics or other antimicrobials, including those
that also utilize p4% citrate, have yet to be established by
large scale RCTs. Nonetheless, some experts have advocated
for the more widespread use of ACLs with hemodialysis
catheters (tunneled and NTHCs) in view of the significant
burden of morbidity and mortality associated with CLABSIs
amongst HD patients.21 While we agree that the findings of
recent studies are encouraging, in view of the potential risks
and costs, we feel that large scale, multicenter RCTs of
specific ACLs are required before recommending their
routine use.
Specialized antimicrobial catheters
Reduction of thrombus and biofilm formation is another
potential method to reduce CLABSIs because they are
often sources for infection. As such, specialized CVCs with
antithrombotic and/or antimicrobial properties (e.g., surface
coatings, antimicrobial- or antithrombotic-impregnated
materials) have been developed. For CVCs in general,
there is insufficient evidence for routine use, although they
may be indicated in circumstances where high rates of
CLABSIs persist despite successful implementation of a
‘bundled’ program to reduce them.13 While there is experi-
mental evidence for silver having antimicrobial properties,26
studies that have assessed the use of silver-coated tunneled
HD catheters have not demonstrated a benefit27,28 and silver-
coated NTHCs have not been studied prospectively. A recent
RCT that included 77 patients requiring acute dialysis
showed significantly less bacterial colonization with a
bismuth-coated NTHC, but no significant difference in the
primary endpoint of time-to-catheter-removal compared
with a conventional NTHC.29 At the present time, the
efficacy and safety of specialized NTHCs for reducing
CLABSIs have not been evaluated in large scale RCTs and
there are potential barriers to their routine use in the future
such as the likelihood of higher costs and, for specialized
NTHCs that might be impregnated with antibiotics, the
possibility of promoting antibiotic resistance.
Catheter dressings
The Centers for Disease Control and Prevention guidelines13
provide some guidance about the types of dressings to be
used on dialysis catheters, but often do not distinguish
between other CVCs and tunneled HD catheters or NTHCs.
Sterile transparent semipermeable dressing or sterile gauze
can be used as line dressings. Gauze dressing are recom-
mended for patients with bleeding or diaphoresis, but must
be changed every 48 h.13 Transparent dressings afford the
benefit of visualizing the line-entry site for evidence of
infection and don’t need to be changed for 7 days.13 During
dressing changes, 2% chlorhexidine should be used to clean
the skin.13 If there is a contraindication to chlorhexidine,
povidodine–iodine or 70% alcohol can be used as alterna-
tives.13 Topical antibacterial ointment or creams (povidone–
iodine or bacitracin/gramicidin/polymixin B) on insertion
sites are not recommended except for consideration on
tunneled dialysis catheters at the time of insertion and at the
end of each dialysis session.13 Chlorhexidine-impregnated
sponge dressing for NTHC cannot be recommended, because
studies showing its efficacy in reducing CLABSIs excluded all
types of HD catheter.
S. aureus decolonization strategies
Bacterial decolonization with intranasal mupirocin has been
shown to significantly reduce the incidence of S. aureus
bacteremia for chronic hemodialysis patients with tunneled
HD catheters.18 We are unaware of any studies that have
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assessed decolonization strategies specifically for patients
with NTHCs.
Given that NTHCs are often used for AKI in the context
of critical illness, studies of decolonization strategies for
unselected ICU patients are relevant to patients who have
NTHCs in that setting. A recent, large, cluster-randomized
trial (n¼ 74,256 patients in 73 ICUs) utilized a 5-day
decolonization protocol consisting of twice daily intranasal
mupirocin and daily bathing with chlorhexidine-impreg-
nated cloths.30 This protocol, when applied to all ICU
patients, significantly reduced the rate of bloodstream infec-
tions (from any pathogen) as compared with a strategy
of applying the same decolonization protocol only to
methicillin-resistant S. aureus carriers or using a strategy
that only involved isolation of methicillin-resistant S. aureus
carriers (i.e., no decolonization).30 It should be noted that
this study did not report any analysis on the basis of whether
or not patients had a NTHC in place and its applicability to
non-ICU patients with NTHCs is tenuous.
INITIATION OF DIALYSIS WITH TEMPORARY CATHETERS
AND OPTIMAL TIMING OF PERMANENT HEMODIALYSIS
ACCESS FOR PATIENTS WITH ACUTE KIDNEY INJURY
Due to the increased risk of infection associated with NTHCs
as compared with tunneled HD catheters, Centers for Disease
Control and Prevention guidelines13 suggest that tunneled
catheters be considered if dialysis access is expected to be
required for more than 3 weeks. For the same reason, Kidney
Disease Outcomes Quality Initiative guidelines (2006 update)
for vascular access suggest that NTHCs should not be used
for more than 1 week at the IJ or SC sites and a maximum of
5 days at the femoral site.8 This recommendation was based
on a study that showed significantly higher infection rates for
patients initiating hemodialysis with NTHCs compared with
tunneled HD catheters and an exponential increase in the risk
of infection after 1 week for NTHCs.31 These recommen-
dations are applicable to patients who are not anticipated
to recover renal function and when dialysis is not urgently
indicated. In such circumstances, initial placement of a
tunneled HD catheter or other access is clearly preferable.
However, NTHCs are often required to initiate urgent dialysis
treatment in the setting of AKI and critical illness when the
duration of dialysis that will be required cannot be readily
predicted.32 In addition, the requirement for specialized
procedural expertise and equipment to place a tunneled HD
catheter may present a barrier to timely initiation of dialysis
treatment and may not be safe or feasible if it requires
transferring a critically ill patient out of the ICU setting.
Finally, while tunneled HD catheters can often be removed as
easily as NTHCs within the first weeks after being inserted,
their removal typically becomes more invasive and time
consuming over time.
As highlighted by the commentary accompanying the
Kidney Disease–Improving Global Outcomes (KDIGO)
Clinical Practice Guidelines for AKI (2012),9 recent large
RCTs that assessed the optimal dose of RRT for AKI (the
ATN and RENAL studies) indicated that RRT was required
for a mean duration of 12–13 days.33,34 It is unclear at this
time if the increased infectious risks associated with a NTHC
outweigh the relative burdens of placing tunneled catheters in
unselected patients with dialysis-requiring AKI. An RCT that
included 34 patients with AKI who required incident dialysis
randomized them to receive femoral NTHCs versus tunneled
femoral HD catheters.35 This study found fewer infections
and better catheter function but more hematomas and longer
insertion times for those assigned to receive a tunneled
catheter.35 While this study suggests an interesting avenue for
future research, its small sample size and other methodologic
limitations prevent it from providing any guidance with
respect to the question of whether the optimal first choice of
dialysis access for AKI is a tunneled HD catheter or a NTHC.
This is especially the case given that the femoral site is not an
ideal first choice of site of catheter insertion in many
situations (for either tunneled or NTHCs) and that tunneled
femoral HD catheters are rarely used in clinical practice. In
the absence of other prospective evidence, the KDIGO
guidelines suggest that NTHCs be used to initiate RRT for
AKI while acknowledging that this suggestion is made
without high-level evidence.9
A related issue is that of the optimal timing for switching
from a NTHC to a tunneled HD catheter when ongoing
dialysis is required following AKI. To our knowledge, and
echoing the commentary accompanying the KDIGO guide-
lines,9 at this time there is no prospective data to guide this
decision and it seems reasonable that a NTHC be replaced
with a tunneled HD catheter once it becomes clear that renal
recovery is unlikely in the near-term.
CHOOSING THE OPTIMAL SITE FOR TEMPORARY
HEMODIALYSIS CATHETER INSERTION
A variety of factors should be taken into consideration to
assess the optimal site for NTHC insertion for a particular
patient. One aspect of this assessment that is unique to
NTHC site selection compared with site selection for other
types of CVCs relates to preservation of the vasculature
should longer term hemodialysis access be required in the
future. As summarized in the KDIGO Guidelines for AKI
(2012),9 whenever possible, the subclavian site should be
avoided for NTHC insertion to reduce the likelihood of
central venous stenosis.9 Use of left-sided IJ and subclavian
veins may also be associated with a greater risk of central
venous stenosis than right-sided veins, possibly as a result
of more contact between the catheter and the vessel wall
throughout the more tortuous anatomic course.9 Taking
this into account, as well as past recommendations and
observational data regarding the likelihood of increased risk
of infection at the femoral site, the KDIGO guidelines
provided an ungraded recommendation regarding site
selection: ‘first choice: right jugular vein; second choice:
femoral vein; third choice: left jugular vein; last choice:
subclavian vein with preference for the dominant side’.9 This
recommendation was made in accordance with prospective,
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observational studies that indicated a higher rate of infection
at the femoral site.36,37 However, there is more recent
evidence that a patient’s body mass index (BMI) should be
an additional factor to be considered in selected circum-
stances. The risk of CLABSI may be lower in patients with
femoral NTHCs if BMI is o24.2 and for IJ NTHCs if the
BMI 428.438 according to a pre-specified analysis from the
Cathedia Study based on the lowest and highest BMI tertiles
of included patients.38 This RCT of femoral versus IJ NTHC
insertion for patients requiring acute dialysis in the ICU
included 750 bed-bound patients who required acute renal
replacement therapy.38 Overall, based on catheter coloniza-
tion rates, this study demonstrated that the use of the femoral
site was not associated with a higher infectious risk.38 An
extension of the Cathedia Study which analyzed data from
those patients who subsequently required a second NTHC
insertion at the alternative site included 134 patients and
demonstrated consistent results: time to catheter-tip coloni-
zation at removal did not differ significantly between femoral
and IJ sites.39 Despite some limitations, such as the
infrequent use of ultrasound for catheter insertions, the
Cathedia Study provided the first high-quality RCT-based
evidence regarding selection of the optimal site for NTHC
insertion. Given the findings of the Cathedia Study, we
suggest that for critically ill, bed-bound patients, in the
absence of overriding considerations, the first choice of site
for NTHC insertion should consider a patient’s ambulatory
status and BMI if below 24 (femoral) or above 28 (IJ). Table 1
details some of the considerations that might favor a
particular site for NTHC insertion.
Another consideration regarding the optimal choice of
insertion site for NTHCs pertains to the risk of catheter
dysfunction and consequent ‘under-dialysis’. Notably, the
Cathedia Study showed no significant differences between
femoral and IJ groups in terms of mean urea reduction ratio
or time to catheter dysfunction.39,40 In addition, no
significant difference in the risk of deep vein thrombosis
(detected using ultrasound screening) was observed.38
SIMULATION-BASED MASTERY TRAINING FOR TEMPORARY
HEMODIALYSIS CATHETER INSERTION
Many medical licensing authorities require candidates seeking
certification in nephrology to be competent in NTHC
insertion. However, traditional nephrology fellowships may
not provide the necessary skills to perform this procedure
safely. Two recent surveys showed that up to 1/3 of
nephrology fellows received little-to-no training and did
not feel confident in inserting NTHCs.3,41 In addition, during
a simulated NTHC insertion assessment of graduating
nephrology fellows from three fellowship programs in the
United States, the mean score on a skills checklist was 53%
items correct (only one fellow met the minimum passing
score on the assessment).2 A 2008 publication called for
evidence-based guidelines to establish standards in
procedural competency for nephrology fellows.42
To ensure today’s medical trainees are proficient and
competent in the procedures they are expected to perform,
simulation-based mastery learning (SBML) has been pro-
moted as an ideal training method.43 Simulation-based
training has been used in medical education to increase
knowledge, provide opportunities for deliberate and safe
practice and shape the development of clinical skills. Mastery
learning is a rigorous form of competency-based learning
where knowledge and skills are measured against a precise
achievement standard.43 All learners must reach this preset
standard so that educational results are equivalent. This is
accomplished by allowing varying practice times for
individual learners, as necessary, to achieve these results.
First-year nephrology fellows who were trained with
SBML for NTHC insertion skills demonstrated 67% higher
scores on a simulated skills exam than graduating fellows
(Po0.001).2 Other medical trainees who participated in an
SBML curriculum for CVC insertion had lower mechanical
complications (including arterial punctures, number of needle
passes, need for line readjustment and failed insertions)
during actual line insertions on patients.44 In addition, SBML
training in central line insertion reduced CLABSI rates by
85%45 and lowered healthcare costs with a 7:1 return on
investment.46 Based on this evidence, we believe that using
SBML for NTHC insertion should be considered at all
nephrology fellowship programs.
CONCLUSIONS
Given that the complications of NTHC insertion are frequent
and can be fatal,2 it is important that nephrologists and
trainees practice techniques that limit these risks and are
evidence based. Recent data suggest, in addition to using real-
time US guidance for all NTHC insertions at the IJ site, US
guidance should also be used for NTHC insertions at
the femoral site.11 Infection-control ‘bundles’ of specific
evidence-based practices to reduce the risk of CLABSIs and
exit-site infections should be implemented in all settings in
which NTHCs are inserted and used. This should include the
use of detailed checklists for the insertion of catheters, as well
as for a daily assessment of whether or not a NTHC is still
Table 1 | Selected factors favoring different temporary (non-
tunneled) hemodialysis catheter insertion sites
Right internal jugular site
Critically ill and bed-bound with body mass index 428
Postoperative aortic aneurysm repair
Ambulatory patient/mobility required for rehabilitation
Femoral sites
Critically ill and bed-bound with body mass index o24
Tracheostomy present or planned in near-term
Need for long-term hemodialysis access present, highly likely or planned
Emergency dialysis required plus inexperienced operator and/or no
access to ultrasound
Left internal jugular site
Contraindications to right internal jugular and femoral sites
Subclavian sites
Contraindications to internal jugular and femoral sites
Right side to be used preferentially
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required or should be removed. Citrate (p4%) catheter locks
should be used for NTHCs rather than heparin.22 There is
currently insufficient evidence to support the routine use of
ACLs or specialized catheters with antimicrobial properties.13
A variety of factors must be taken into consideration when
determining the optimal site for NTHC insertion. If possible,
the subclavian site should be avoided due to the long-term
risk of central venous stenosis.9 RCT evidence now suggests
that the femoral site may not be associated with a higher risk
of infection and is possibly even preferable in patients who
are critically ill and bed-bound with a BMI less than 24.38
Last, the use of SBML to teach NTHC insertion to nephrology
fellows has been shown to significantly improve their
procedural competency.4 This type of educational program
can reduce the risk of CLABSIs,45 result in significant cost
savings46 and should be considered for implementation by all
nephrology training programs.
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